Literature DB >> 14749091

Do antidepressants regulate how cortisol affects the brain?

Carmine M Pariante1, Sarah A Thomas, Simon Lovestone, Andrew Makoff, Robert W Kerwin.   

Abstract

Although the effects of antidepressants on glucocorticoid hormones and their receptors are relevant for the therapeutic action of these drugs, the molecular mechanisms underlying these effects are unclear. Studies in depressed patients, animals and cellular models have demonstrated that antidepressants increase glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) expression and function; this, in turn, is associated with enhanced negative feedback by endogenous glucocorticoids, and thus with reduced resting and stimulated hypothalamic-pituitary-adrenal (HPA) axis activity. In a series of studies conducted over the last few years, we have shown that antidepressants modulate GR function in vitro by inhibiting membrane steroid transporters that regulate the intracellular concentration of glucocorticoids. In this paper, we will review the effects of membrane steroid transporters and antidepressants on corticosteroid receptors. We will then present our unpublished data on GR live microscopy in vitro, showing that ligand-induced translocation of the GR starts within 30 seconds and is completed within minutes. Furthermore, we will present our new data using an in situ brain perfusion model in anaesthetised guinea-pigs, showing that entry of cortisol to the brain of these animals is limited at the blood-brain barrier (BBB). Finally, we will present a comprehensive discussion of our published findings on the effects of chemically unrelated antidepressants on membrane steroid transporters, in mouse fibroblasts and rat cortical neurones. We propose that antidepressants in humans could inhibit steroid transporters localised on the BBB and in neurones, like the multidrug resistance p-glycoprotein, and thus increase the access of cortisol to the brain and the glucocorticoid-mediated negative feedback on the HPA axis. Enhanced cortisol action in the brain might prove to be a successful approach to maximise therapeutic antidepressant effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749091     DOI: 10.1016/j.psyneuen.2003.10.009

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  49 in total

1.  Blunted HPA Axis Activity in Suicide Attempters Compared to those at High Risk for Suicidal Behavior.

Authors:  Nadine M Melhem; John G Keilp; Giovanna Porta; Maria A Oquendo; Ainsley Burke; Barbara Stanley; Thomas B Cooper; J John Mann; David A Brent
Journal:  Neuropsychopharmacology       Date:  2015-10-09       Impact factor: 7.853

2.  Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.

Authors:  Cornelius Schüle; Thomas C Baghai; Daniela Eser; Peter Zwanzger; Martina Jordan; Renate Buechs; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2006-04-22       Impact factor: 4.530

Review 3.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  NeuroRx       Date:  2005-01

4.  A Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder.

Authors:  E Sherwood Brown; Nasreen Sayed; Erin Van Enkevort; Alexandra Kulikova; Alyson Nakamura; David A Khan; Elena I Ivleva; Prabha Sunderajan; Bruce G Bender; Traci Holmes
Journal:  J Allergy Clin Immunol Pract       Date:  2018-03-01

5.  Clomipramine in vitro reduces glucocorticoid receptor function in healthy subjects but not in patients with major depression.

Authors:  Livia A Carvalho; Mario F Juruena; Andrew S Papadopoulos; Lucia Poon; Rob Kerwin; Anthony J Cleare; Carmine M Pariante
Journal:  Neuropsychopharmacology       Date:  2008-03-26       Impact factor: 7.853

6.  Exogenous glucocorticoids decrease subgenual cingulate activity evoked by sadness.

Authors:  Keith D Sudheimer; James L Abelson; Stephan F Taylor; Brian Martis; Robert C Welsh; Christine Warner; Mira Samet; Andrea Manduzzi; Israel Liberzon
Journal:  Neuropsychopharmacology       Date:  2012-12-03       Impact factor: 7.853

7.  Differences in FKBP51 regulation following chronic social defeat stress correlate with individual stress sensitivity: influence of paroxetine treatment.

Authors:  Klaus V Wagner; Daria Marinescu; Jakob Hartmann; Xiao-Dong Wang; Christiana Labermaier; Sebastian H Scharf; Claudia Liebl; Manfred Uhr; Florian Holsboer; Marianne B Müller; Mathias V Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

8.  Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: differential regulation of specific exons by antidepressants and corticosterone.

Authors:  Y Dwivedi; H S Rizavi; G N Pandey
Journal:  Neuroscience       Date:  2006-02-24       Impact factor: 3.590

Review 9.  Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids.

Authors:  Carmine M Pariante
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 10.  [Childhood maltreatment and adult psychopathology: pathways to hypothalamic-pituitary-adrenal axis dysfunction].

Authors:  Marcelo F Mello; Alvaro A Faria; Andrea F Mello; Linda L Carpenter; Audrey R Tyrka; Lawrence H Price
Journal:  Braz J Psychiatry       Date:  2009-10       Impact factor: 2.697

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.